Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
478 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Follicular Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Follicular Lymphoma - Pipeline Review, H2 2015', provides an overview of the Follicular Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Follicular Lymphoma Overview 10 Therapeutics Development 11 Pipeline Products for Follicular Lymphoma - Overview 11 Pipeline Products for Follicular Lymphoma - Comparative Analysis 12 Follicular Lymphoma - Therapeutics under Development by Companies 13 Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 18 Follicular Lymphoma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Follicular Lymphoma - Products under Development by Companies 22 Follicular Lymphoma - Products under Investigation by Universities/Institutes 28 Follicular Lymphoma - Companies Involved in Therapeutics Development 29 AbbVie Inc. 29 Affimed Therapeutics AG 30 AmpliMed Corporation (Inactive) 31 Bayer AG 32 BeiGene(Beijing) Co.,Ltd 33 Bio-Path Holdings, Inc. 34 Biocon Limited 35 Biogenomics Limited 36 Biothera, Inc. 37 Boehringer Ingelheim GmbH 38 Bristol-Myers Squibb Company 39 Celgene Corporation 40 Celltrion, Inc. 41 Cellular Biomedicine Group, Inc. 42 Coherus BioSciences, Inc. 43 CTI BioPharma Corp. 44 Curis, Inc. 45 Dynavax Technologies Corporation 46 Eisai Co., Ltd. 47 EpiZyme, Inc. 48 F. Hoffmann-La Roche Ltd. 49 Genentech, Inc. 50 Gilead Sciences, Inc. 51 GlaxoSmithKline Plc 52 Hutchison MediPharma Limited 53 ImmunoGen, Inc. 54 Immunomedics, Inc. 55 Infinity Pharmaceuticals, Inc. 56 Johnson & Johnson 57 Karyopharm Therapeutics, Inc. 58 Kite Pharma, Inc. 59 Les Laboratoires Servier SAS 60 MedImmune, LLC 61 Medivation, Inc. 62 Merck & Co., Inc. 63 Millennium Pharmaceuticals, Inc. 64 Mirati Therapeutics Inc. 65 MorphoSys AG 66 Nordic Nanovector ASA 67 Novartis AG 68 Ono Pharmaceutical Co., Ltd. 69 Pfizer Inc. 70 Pharmacyclics, Inc. 71 Portola Pharmaceuticals, Inc. 72 ProNAi Therapeutics, Inc. 73 Sandoz International GmbH 74 Seattle Genetics, Inc. 75 TG Therapeutics, Inc. 76 Follicular Lymphoma - Therapeutics Assessment 77 Assessment by Monotherapy Products 77 Assessment by Combination Products 78 Assessment by Target 79 Assessment by Mechanism of Action 84 Assessment by Route of Administration 88 Assessment by Molecule Type 90 Drug Profiles 92 abexinostat hydrochloride - Drug Profile 92 acalabrutinib - Drug Profile 95 AFM-11 - Drug Profile 98 alisertib - Drug Profile 99 ASN-002 - Drug Profile 103 atezolizumab - Drug Profile 104 azacitidine - Drug Profile 108 Betalutin - Drug Profile 112 BGB-3111 - Drug Profile 114 bortezomib - Drug Profile 115 BP-100102 - Drug Profile 121 buparlisib hydrochloride - Drug Profile 122 BVX-20 - Drug Profile 126 CBM-C19.1 - Drug Profile 127 CBM-C20.1 - Drug Profile 128 Cellular Immunotherapy to Target CD22 for B-Cell Leukemia and Lymphoma - Drug Profile 130 Cellular Immunotherapy to Target GM-CSF for Oncology - Drug Profile 132 cerdulatinib - Drug Profile 134 copanlisib hydrochloride - Drug Profile 136 CUDC-907 - Drug Profile 140 daratumumab - Drug Profile 142 dasiprotimut-T - Drug Profile 146 denintuzumab mafodotin - Drug Profile 148 duvelisib - Drug Profile 149 E-7449 - Drug Profile 152 entospletinib - Drug Profile 153 epratuzumab - Drug Profile 154 GS-9901 - Drug Profile 159 GSK-2816126 - Drug Profile 160 HMPL-523 - Drug Profile 161 ibrutinib - Drug Profile 162 ibrutinib + ublituximab + TGR-1202 - Drug Profile 169 idelalisib - Drug Profile 170 IGN-002 - Drug Profile 173 imexon - Drug Profile 174 IMGN-529 - Drug Profile 176 IMMU-114 - Drug Profile 178 Imprime PGG - Drug Profile 179 inebilizumab - Drug Profile 184 inebilizumab + MEDI-0680 - Drug Profile 186 inebilizumab + rituximab - Drug Profile 187 interferon alfa-2b - Drug Profile 188 interferon alfa-2b - Drug Profile 189 ixazomib citrate - Drug Profile 190 JNJ-64052781 - Drug Profile 194 KTEC-19 - Drug Profile 195 lenalidomide - Drug Profile 197 mocetinostat - Drug Profile 202 Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile 205 MOR-208 - Drug Profile 206 nivolumab - Drug Profile 208 obinutuzumab - Drug Profile 216 Oncoquest - Drug Profile 219 pembrolizumab - Drug Profile 221 pidilizumab - Drug Profile 230 pixantrone dimaleate - Drug Profile 232 PNT-2258 - Drug Profile 236 polatuzumab vedotin - Drug Profile 238 rituximab biosimilar - Drug Profile 240 rituximab biosimilar - Drug Profile 242 rituximab biosimilar - Drug Profile 243 rituximab biosimilar - Drug Profile 244 rituximab biosimilar - Drug Profile 245 rituximab biosimilar - Drug Profile 246 rituximab biosimilar - Drug Profile 247 S-055746 - Drug Profile 248 SD-101 - Drug Profile 249 selinexor - Drug Profile 251 SGN-CD70A - Drug Profile 257 SH-7129 - Drug Profile 258 tazemetostat - Drug Profile 260 temsirolimus - Drug Profile 262 TGR-1202 - Drug Profile 264 tisagenlecleucel-T - Drug Profile 266 ublituximab + TGR-1202 - Drug Profile 269 ulocuplumab - Drug Profile 270 urelumab - Drug Profile 272 Vaccine for Follicular Lymphoma - Drug Profile 274 Vaccine for Multiple Myeloma and Follicular Lymphoma - Drug Profile 275 venetoclax - Drug Profile 276 vorinostat - Drug Profile 279 Follicular Lymphoma - Recent Pipeline Updates 283 Follicular Lymphoma - Dormant Projects 459 Follicular Lymphoma - Discontinued Products 461 Follicular Lymphoma - Product Development Milestones 462 Featured News & Press Releases 462 Appendix 471 Methodology 471 Coverage 471 Secondary Research 471 Primary Research 471 Expert Panel Validation 471 Contact Us 471 Disclaimer 472
List of Tables
Number of Products under Development for Follicular Lymphoma, H2 2015 17 Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2015 18 Number of Products under Development by Companies, H2 2015 20 Number of Products under Development by Companies, H2 2015 (Contd..1) 21 Number of Products under Development by Companies, H2 2015 (Contd..2) 22 Number of Products under Development by Companies, H2 2015 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2015 24 Comparative Analysis by Late Stage Development, H2 2015 25 Comparative Analysis by Clinical Stage Development, H2 2015 26 Comparative Analysis by Early Stage Development, H2 2015 27 Products under Development by Companies, H2 2015 28 Products under Development by Companies, H2 2015 (Contd..1) 29 Products under Development by Companies, H2 2015 (Contd..2) 30 Products under Development by Companies, H2 2015 (Contd..3) 31 Products under Development by Companies, H2 2015 (Contd..4) 32 Products under Development by Companies, H2 2015 (Contd..5) 33 Products under Investigation by Universities/Institutes, H2 2015 34 Follicular Lymphoma - Pipeline by AbbVie Inc., H2 2015 35 Follicular Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 36 Follicular Lymphoma - Pipeline by AmpliMed Corporation (Inactive), H2 2015 37 Follicular Lymphoma - Pipeline by Bayer AG, H2 2015 38 Follicular Lymphoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 39 Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H2 2015 40 Follicular Lymphoma - Pipeline by Biocon Limited, H2 2015 41 Follicular Lymphoma - Pipeline by Biogenomics Limited, H2 2015 42 Follicular Lymphoma - Pipeline by Biothera, Inc., H2 2015 43 Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 44 Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 45 Follicular Lymphoma - Pipeline by Celgene Corporation, H2 2015 46 Follicular Lymphoma - Pipeline by Celltrion, Inc., H2 2015 47 Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 48 Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2015 49 Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H2 2015 50 Follicular Lymphoma - Pipeline by Curis, Inc., H2 2015 51 Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2015 52 Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 53 Follicular Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 54 Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 55 Follicular Lymphoma - Pipeline by Genentech, Inc., H2 2015 56 Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 57 Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 58 Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 59 Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 60 Follicular Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 61 Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 62 Follicular Lymphoma - Pipeline by Johnson & Johnson, H2 2015 63 Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 64 Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015 65 Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H2 2015 66 Follicular Lymphoma - Pipeline by MedImmune, LLC, H2 2015 67 Follicular Lymphoma - Pipeline by Medivation, Inc., H2 2015 68 Follicular Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 69 Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 70 Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015 71 Follicular Lymphoma - Pipeline by MorphoSys AG, H2 2015 72 Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 73 Follicular Lymphoma - Pipeline by Novartis AG, H2 2015 74 Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 75 Follicular Lymphoma - Pipeline by Pfizer Inc., H2 2015 76 Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015 77 Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 78 Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015 79 Follicular Lymphoma - Pipeline by Sandoz International GmbH, H2 2015 80 Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 81 Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 82 Assessment by Monotherapy Products, H2 2015 83 Assessment by Combination Products, H2 2015 84 Number of Products by Stage and Target, H2 2015 86 Number of Products by Stage and Mechanism of Action, H2 2015 91 Number of Products by Stage and Route of Administration, H2 2015 95 Number of Products by Stage and Molecule Type, H2 2015 97 Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 289 Follicular Lymphoma - Dormant Projects, H2 2015 465 Follicular Lymphoma - Dormant Projects (Contd..1), H2 2015 466 Follicular Lymphoma - Discontinued Products, H2 2015 467
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
